Genetic Factors Affecting Adverse Events from Co-trimoxazole in Lupus Patients
Author Information
Author(s): Soejima Makoto, Sugiura Tomoko, Kawaguchi Yasushi, Kawamoto Manabu, Katsumata Yasuhiro, Takagi Kae, Nakajima Ayako, Mitamura Tadayuki, Mimori Akio, Hara Masako, Kamatani Naoyuki
Primary Institution: Institute of Rheumatology, Tokyo Women's Medical University School of Medicine
Hypothesis
The study investigates the association between genetic polymorphisms in the NAT2 gene and adverse events with co-trimoxazole in patients with systemic lupus erythematosus.
Conclusion
Lack of the NAT2*4 haplotype is associated with a higher frequency of adverse events from co-trimoxazole in Japanese patients with systemic lupus erythematosus.
Supporting Evidence
- 54 patients received prophylactic doses of co-trimoxazole.
- Adverse events occurred in 18 patients, with 2 experiencing severe events.
- 71.4% of slow acetylators experienced adverse events compared to 27.7% of fast acetylators.
Takeaway
Some people have genes that make them more likely to get sick from a medicine called co-trimoxazole, especially if they don't have a specific gene variant.
Methodology
The study included a cohort of 166 patients with systemic lupus erythematosus, with genotyping performed to assess NAT2 gene polymorphisms and their association with adverse events from co-trimoxazole.
Limitations
The study is limited to Japanese patients, which may affect the generalizability of the findings to other populations.
Participant Demographics
All participants were Japanese patients with systemic lupus erythematosus.
Statistical Information
P-Value
0.034
Confidence Interval
1.34–4.99
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website